Kathryn A. Carolin
Wayne State University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Kathryn A. Carolin.
Cancer | 2002
Lisa A. Newman; James O. Mason; David J. Cote; Yael Vin; Kathryn A. Carolin; David L. Bouwman; Graham A. Colditz
African‐American women are at increased risk for breast cancer mortality compared with white American women, and the extent to which socioeconomic factors account for this outcome disparity is unclear.
Cancer | 2002
Lisa A. Newman; Scott Bunner; Kathryn A. Carolin; David L. Bouwman; Mary Ann Kosir; Michael T. White; Ann G. Schwartz
African‐American women face an increased risk of early‐onset breast carcinoma compared to white American women, and breast carcinoma has been reported to be particularly aggressive in premenopausal women.
Modern Pathology | 2003
Michelle L. Bonnett; Tracie Wallis; Michelle Rossmann; Nat L. Pernick; David L. Bouwman; Kathryn A. Carolin; Daniel W. Visscher
Appropriate follow-up of patients with needle core breast biopsies (NCBB) showing atypical hyperplasia remains unclear because previous studies show that subsequent open biopsies in variable proportions of these patients reveal ductal carcinoma in situ (DCIS) or even invasive carcinoma, indicating significant sampling artifact. NCBB with diagnoses of atypia were morphologically classified into groups as follows: I, ALH (n = 24); II, ADH with minimal cytologic atypism (n = 90); III, atypia, other (9 columnar, 2 apocrine, 11 atypical papillary); IV, severe ADH/borderline DCIS (n = 31). Mammographic and histologic features, including the number of foci of atypia in the NCBB and the calcification span, were then correlated with presence of DCIS or invasive tumor in subsequent open excisions. Open excisional biopsies showed more severe lesions in 12% of Group I–III cases (8% in Group I, 9% in Group II, and 27% in Group III), of which 15 were DCIS and one was an invasive tubular carcinoma (0.3 cm). Of the DCIS, 60% (n = 9) were ≤5 mm, and 13 of 15 (87%) were low grade. The NCBB cavity was immediately adjacent to the more severe lesions in 88% (n = 14) of cases, in keeping with sampling error. The subset showing severe ADH with borderline nuclear features in contrast was associated with a high likelihood (63%) of DCIS in follow-up excisions. NCBB with atypical papillary features also showed a high frequency of DCIS (4/11, 36%) in subsequent open excisions. Other factors associated with more severe lesions on open biopsy included the number of atypical foci in the NCBB (>4, P < .05) and the mammographic calcification span (>2.0 cm, P < .0001). Atypical lesions diagnosed in NCBB samples are radiographically and morphologically heterogeneous, accounting for the variable frequency of DCIS or invasive neoplasm identified in subsequent open excisions, which are usually focal, low grade, and a consequence of sampling artifact (i.e., adjacent to the NCBB cavity). DCIS is more likely if microcalcifications are mammographically extensive or if atypia is multifocal or is associated with borderline cytologic features.
Annals of Surgical Oncology | 2003
Lisa A. Newman; Nat Pernick; Volkan Adsay; Kathryn A. Carolin; Philip I. Philip; Susan Sipierski; David L. Bouwman; Mary Ann Kosir; Michael T. White; Daniel W. Visscher
Background: The benefits of primary tumor downstaging and assessment of chemoresponsiveness have resulted in expanded applications for induction chemotherapy. However, the pathologic evaluation and prognostic significance of response in preoperatively treated lymph nodes have not been defined.Methods: The axillary lymph nodes of 71 patients with locally advanced breast cancer treated with induction chemotherapy were evaluated for histological evidence of tumor regression as defined by the presence of nodal fibrosis, mucin pools, or aggregates of foamy histiocytes.Results: Complete pathologic response in the breast and axilla occurred in 10 patients (14%); 19 (26.8%) had evidence of tumor regression in 1 or more lymph nodes. Patients without nodal metastases and no evidence of tumor regression had the best outcome (median disease-free survival, 31.5 months; relapse rate, 27%). Patients with residual nodal metastases and no evidence of treatment effect had the worst outcome (median disease-free survival, 19.8 months; relapse rate, 55%). The median disease-free survival was 22.1 months, and the relapse rate was 32% for patients with histopathologic evidence of tumor regression in the axillary lymph nodes.Conclusions: Detection of treatment effect in axillary lymph nodes after induction chemotherapy identifies a subset of patients with an outcome intermediate between that of completely node-negative and node-positive patients. The axillary lymph nodes of patients receiving preoperative chemotherapy should be routinely analyzed for the presence of these features.
American Journal of Pathology | 2007
Malathy P.V. Shekhar; Steven J. Santner; Kathryn A. Carolin; Larry Tait
American Journal of Surgery | 2003
Keiva L Bland; Rebecca Perczyk; Wei Du; Christine Rymal; Prathima Koppolu; Ruthie McCrary; Kathryn A. Carolin; Mary Ann Kosir
Breast Journal | 2002
Kathryn A. Carolin; Samuel Tekyi-Mensah; Helen Pass
/data/revues/00029610/v184i5/S0002961002010103/ | 2011
Cary S. Kaufman; Barbara Bachman; Peter Littrup; Michael T. White; Kathryn A. Carolin; Laurie Freman-Gibb; Darius Francescatti; Lewis H. Stocks; J. Stanley Smith; C.Alan Henry; Lisa Bailey; Jay K. Harness; Rache M. Simmons
Breast Cancer Research and Treatment | 2001
Lisa A. Newman; Kathryn A. Carolin; David L. Bouwman; M. Kosir; M. White; T. Wallis; J. Barnwell; Daniel W. Visscher
Breast Cancer Research and Treatment | 2001
M. Rossmann; Kathryn A. Carolin; L Freeman-Gibb; M Segal; L Newman; David L. Bouwman